Alzheimer’s Disease
- Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup
- Alzheimer’s Disease Facts and Figures 2024
- Focusing on earlier diagnosis of Alzheimer’s disease
- For Patients: Treatments for Alzheimer’s
- Alzheimer’s Disease: Key Insights from Two Decades of Clinical Trial Failures
- Alzheimer’s disease drug development pipeline
- Treatment with GLP-1 RAs and incidence of dementia
- Donanemab in Early Symptomatic Alzheimer Disease
- Alzforum: news and information dedicated to Alzheimer’s disease
Amyotrophic Lateral Sclerosis
Migraine
- Frequently Asked Questions About Migraine Symptoms
- Migraine Burden of Disease: From the Patient’s Experience to a Socio-Economic View
- Atogepant for the Preventive Treatment of Migraine
Multiple Sclerosis (MS)
- Clinician Pocket Guide: What to Screen For and What to Follow When Using Disease-Modifying Therapies (DMTs)
- MS, COVID-19 and vaccines – updated global advice
- Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
- Aging and efficacy of disease-modifyingtherapies in multiple sclerosis: a meta-analysis of clinical trials
- Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50 years
- BEACON: BEtaferon prospective study on Adherence, COping and Nurse support): Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b
- Practice Guideline: Disease-modifying Therapies for Adults with Multiple Sclerosis
- Shared decision-making in multiple sclerosis
- Shared Decision-Making in Multiple Sclerosis Management
- The SHARE Approach: Essential Steps of Shared Decision making: Expanded Reference Guide with Sample Conversation Starters
- Guidelines of the Consortium of MS Centers MRI Protocol for the Diagnosis and Follow-up of MS
- Comparison of efficacy and safety of oral agents for the treatment of relapsing–remitting multiple sclerosis
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
- The Use of Disease-Modifying Therapies in MS
- Adherence — Patient Information
- Resources for You and Your Practice
- Mobile Applications for People with Multiple Sclerosis (MS)
- Pregnancy and Reproductive Issues
- Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis
- Disease-modifying Therapies for MS
Muscular Dystrophy
- Limb-girdle muscular dystrophy
- Gene Delivery for Limb-Girdle Muscular Dystrophy Type 2D by Isolated Limb Infusion
Parkinson’s Disease
- Parkinson’s Disease Fact Sheet
- The On-Off Phenomenon
- On-Off Phenomenon: When Levodopa Stops Working as Well
Stroke
- Impact of Echocardiographic Parameters on Recurrent Stroke in the Randomized REDUCE PFO Cryptogenic Stroke Trial
- Heterogeneity of Treatment Effects in an Analysis of Pooled Individual Patient Data From Randomized Trials of Device Closure of Patent Foramen Ovale After Stroke
- Etiologic Workup in Cases of Cryptogenic Stroke: A Systematic Review of International Clinical Practice Guidelines
- A Patient Guide to Understanding Strokes of Unknown Cause
- 2019 Updated Healthcare Professional Guide Understanding Diagnosis and Treatment of Cryptogenic Stroke
- RESPECT Trial- Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke
- REDUCE Trial- Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke
- Reducing Door-to-Needle Times using Lean Principles
- Implementation of Telemedicine Within Stroke Systems of Care
- Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke
- Clinical Policy: Use of Intravenous Tissue Plasminogen Activator for the Management of Acute Ischemic Stroke in the Emergency Department
- Optimizing Stroke Systems of Care
- Effect of Telestroke on Emergent Stroke Care and Outcomes
- TeleStroke Simulation Video
- Know the Signs and Symptoms of a Stroke – Patient Handout
- American Heart Association / American Stroke Association Guidelines for the Primary Prevention of Stroke
- Recognize Warning Signs of a Stroke (Act FAST)
- Proposal for Updated Nomenclature and Classification of Potential Causative Mechanism in Patent Foramen Ovale-Associated Stroke
- American Academy of Neurology practice advisory update: Patent foramen ovale and secondary stroke prevention
- REDUCE trial: Five-Year Outcomes of PFO Closure or Antiplatelet Therapy for Cryptogenic Stroke
- Recurrent Stroke Reduction with Patent Foramen Ovale Closure versus Medical Therapy Based on Patent Foramen Ovale Characteristics: A Meta-Analysis of Randomized Controlled Trials
- CLOSE trial: Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke
